The venture is a spinout from Google's DeepMind unit and aims to use generative AI to accelerate the drug discovery process. Sources indicate the funding talks could potentially push the startup's valuation as high as $50 billion if the round is completed at the upper end of investor expectations.
Tuesday, October 20, 2026
Story
Isomorphic Labs Targets $40 Billion to $50 Billion Valuation
Startups13 days ago
Isomorphic Labs is currently in discussions with investors to secure a new round of funding to expand its artificial intelligence platform for pharmaceutical research. The company is negotiating a valuation of at least $40 billion, according to sources familiar with the matter.
Looking for more context or analysis?
Tilt chat provides reliable, tailored insights, alerts, and automations.